Skip to main content
SpringerLink
Log in

Interleukin-6, a new target for therapy in multiple myeloma?

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

During the past few years much insight has been gained into the immunobiology of multiple myeloma. It has become evident that the growth of myeloma cells is regulated by cytokines, notably interleukin-6. In this paper a brief review is given of the evidence derived from in vitro as well as in vivo observations that interleukin-6 is involved in the pathogenesis of multiple myeloma, and the implications of these findings for the development of new therapeutic strategies are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aarden LA, Lansdorp P, de Groot E (1985) A growth factor for B cell hybridomas produced by human monocytes. Lymphokines 10: 175–178

    Google Scholar 

  2. Anderson KC, Jones R, Morimoto C, Leavitt P, Barut B (1989) Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73: 1915–1924

    Google Scholar 

  3. Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of IL-6, a potent myeloma growth factor, as a reflection of disease activity in plasma cell dyscrasias. J Clin Invest 84: 2008–2011

    Google Scholar 

  4. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A (1992) C-Reactive protein andβ-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733–737

    Google Scholar 

  5. Bataille R, Chappard D, Klein B (1992) Mechanism of bone lesions in MM. Hematol Oncol Clin North Am 6: 285–295

    Google Scholar 

  6. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R (1986) High-dose melphalan with bone marrow transplantation for multiple myeloma. Blood 67: 1298–1301

    Google Scholar 

  7. Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F (1988) Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 72: 2015–2019

    Google Scholar 

  8. Bergui L, Schena M, Gridano G, Riva M, Caligaris-Cappio F (1989) IL-3 and IL-6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med170: 613–618

    Google Scholar 

  9. Buzaid AC, Durie BGM (1988) Management of refractory myeloma a review. J Clin Oncol 6: 889

    Google Scholar 

  10. Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M, Zallone AZ, Marchisio PC (1991) Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77: 2688–2693

    Google Scholar 

  11. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I (1990) The role of interleukin-1 and tumour necrosis factor-α in human multiple myeloma. Br J Haematol 74: 424–431

    Google Scholar 

  12. Damme J Van, Opdenakker G, Simpson R, Rubira M, Cayphas S, Vink A, Billian A, Van Snick J (1987) Identification of the human 26-kDa protein, interferon B2 as a B cell hybridoma/ plasmacytoma growth factor induced by IL-1 and TNF. J Exp Med 165: 914–919

    Google Scholar 

  13. Durie B, Grogan T, Vela L, Frutiger Y, Christiansen J (1989) IL-6 antibodies and macrophage depletion allow delineation of the sources and effects of IL-6 in myeloma bone marrow. Blood 74 [Suppl]: 200A

    Google Scholar 

  14. Emilie D, Crevon M, Auffredou M, Galamand P (1988) Glucocorticosteroid-dependent synergy between IL-1 and IL-6 for human B lymphocyte differentiation. Eur J Immunol 18: 2043–2047

    Google Scholar 

  15. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A, Lowenberg B, Nikoskelainen J, Reffers J, Samson D, Verdonck L, Volin L, et al. (1991) Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325: 1267–1273

    Google Scholar 

  16. Heinrich PC, v. Castell J, Andus T (1990) Interleukin-6 and the acute-phase response (review). Biochem J 265: 621–636

    Google Scholar 

  17. Herrmann F, Andreeff M, Gruss HJ, Brach MA, Lubbert M, Mertelsmann R (1991) IL-4 inhibits growth of multiple myelomas by suppressing IL-6 expression. Blood 78: 2070–2074

    Google Scholar 

  18. Hirano T, Yasukawa K, Harada H, Taga T, Watanaba Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Tanigushi T, Kishimoto T, et al. (1986) Complementary DNA for a novel interleukin (BSF2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73–76

    Google Scholar 

  19. Jernberg-Wiklund H, Pettersson M, Nilsson K 1991) Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur J Haematol 46: 231–239

    Google Scholar 

  20. Jernberg-Wiklund H, Pettersson M, Carlsson M, Nilsson K (1992) Increase in IL-6 and IL-6 receptor expression in a human MM cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 6: 310–318

    Google Scholar 

  21. Jourdan M, Zhang XG, Portier M, Boiron J, Bataille R, Klein B (1991) IF alpha induces autocrine production of IL-6 in myeloma cell lines. Blood 147: 4402–4407

    Google Scholar 

  22. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF2/IL-6 for human multiple myelomas. Nature 332: 83–85

    Google Scholar 

  23. Kawano M, Tanaka H, Ishikawa H, Nobuyoshi M, Iwato K, Asaoku H, Tanabe O, Kuramoto A (1989) IL-1 accelerates autocrine growth of myeloma cells through IL-6 in human myeloma. Blood 73: 2145–2148

    Google Scholar 

  24. Kishimoto T (1989) The biology of interleukin-6 (review). Blood 74: 1–10

    Google Scholar 

  25. Klein B, Bataille R (1991) Third Eurage symposium on monoclonal gammapathies (abstract) Brussels, Sept. 1991

  26. Klein B, Bataille R (1992) Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 6:

  27. Klein B, Zhang XG, Jourdan M, Content J, Houssiau JC, Aarden L, Piechaczyk M, Bataille R (1989) Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by IL-6. Blood 73: 517–526

    Google Scholar 

  28. Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R (1990) IL-6 is the central tumor growth factor in vitro and in vivo in MM. Eur J Cytokine Net 4: 193–201

    Google Scholar 

  29. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Mannoni P, Sany J, Bataille R, et al. (1991) Murine antiIL-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198–1204

    Google Scholar 

  30. Kooten C Van, van Oers MHJ, Aarden L (1990) IL-6 enhances human Ig production, but not as a terminal differentiation factor for B lymphocytes. Res Immunol 141: 341–356

    Google Scholar 

  31. Kreitman R, Siegall C, FitzGerald D, Epstein J, Barlogie B, Pastan I (1992) IL-6 fused to a mutant form ofPseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood 79: 1775–1780

    Google Scholar 

  32. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD (1990) IL-6 stimulates osteoclast-like multinucleated cell formation in long-term human marrow cultures by inducing IL-1 release. J Immunol 144: 4226–4230

    Google Scholar 

  33. Levi Y, Fermand JP, Navarro S, Schmitt C, Vainchencken W, Seligmann M, Brauet JC (1990) IL-6 dependence of spontaneous in vitro differentiation of B cells from patients with IgM gammapathy. Proc Natl Acad Sci USA 87: 3309–3313

    Google Scholar 

  34. Mackiewicz A, Sckooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 upregulates expression of acute phase proteins. J Immunol 149: 2021–2027

    Google Scholar 

  35. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T (1988) The essential role of BSF-2 (IL-6) for the terminal differentiation of B cells. J Exp Med 167: 332–344

    Google Scholar 

  36. Nachbaur DM, Herold M, Maneschg A, Huber H (1991) Serum levels of IL-6 in MM and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 62: 54–58

    Google Scholar 

  37. Nakamura M, Merchav S, Carter A (1989) Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol 143: 3543–3546

    Google Scholar 

  38. Nordan RP, Potter M (1986) A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 233: 566–569

    Google Scholar 

  39. Nordan R, Pumphrey J, Rudikoff S (1987) Purification and NH2-terminal sequence of a plasmacytoma growth-factor derived from the msurine macrophage cell line P 388 D1. J Immunol 139: 813–817

    Google Scholar 

  40. Portier M, Rajzbaum G, Zhang XG, Attal M, Rusalen C, Wijdenes J, Mannoni P, Maraninchi D, Piechaczyk M, Bataille R, Klein B (1991) In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 21: 1759–1762

    Google Scholar 

  41. Potter M, Boyce C (1962) Induction of plasma cell neoplasms in Balb/c mice with mineral oil and mineral oil adjuvants. Nature 193: 1086–1089

    Google Scholar 

  42. Scala G, Quinto I, Ruocco M, Mallardo M, Squitieri B, Venuta S (1990) Expression of an exogenous IL-6 gene in human EBV B cells confers growth advantage and in vivo tumorigenicity. J Exp Med 172: 61–68

    Google Scholar 

  43. Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, Osborne RJ, Slevin ML & Malpas JS (1987) Multiple myeloma treated with high-dose intravenous melphalan. Br J Haematol 66: 55–62

    Google Scholar 

  44. Shimizu S, Yoshioka R, Hirose Y, Sugai S, Tachibana J, Konda S (1989) Establishment of two IL-6 (BSF2)-dependent human bone marrow-derived myeloma cell lines. J Exp Med 169: 339–344

    Google Scholar 

  45. Snick J Van, Cayphas S, Szikora J, Renauld J, Van Roost E, Boon T, Simpson R (1988) cDNA cloning of murine IL-HP1: homology with human IL-6. Eur J Immunol 18: 193–197

    Google Scholar 

  46. Sporn JR, McIntyre OR (1986) Chemotherapy of previously untreated myeloma patients: an analysis of recent treatment results. Semin Oncol 13: 318–325

    Google Scholar 

  47. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1989) IgG1 plasmacytosis in IL-6 transgenic mice. Proc Natl Acad Sci USA 86: 7547–7551

    Google Scholar 

  48. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1992) Generation of plasmacytomas with the chromosomal translocation t (12; 15) in IL-6 transgenic mice. Proc Natl Acad Sci USA 89: 232–235

    Google Scholar 

  49. Suzuki H, Xasukawa K, Saito T, Goitsuka R, Hasegawa A, Oksugi Y, Taga T, Kishimoto T (1992) Anti-human IL-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 22: 1989–1993

    Google Scholar 

  50. Tanabe O, Kawano M, Tanaka H, Iwato K, Aspoku H, Ishikawa H, Nobuyoshi M, Hirawo T, Kishimoto T, Kuramoto A (1989) BSF 2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am J Hematol 31: 258–262

    Google Scholar 

  51. Tohyama N, Karasuyama H, Tada T (1990) Growth autonomy and tumorigenicity of IL-6-dependent B cells transfected with IL-6 cDNA. J Exp Med 171: 389–400

    Google Scholar 

  52. Tosato G, Gerrard T, Goldman W, Pike S (1988) Stimulation of EBV-activated human B cells by monocytes and monocyte products. J Immunol 140: 4329–4336

    Google Scholar 

  53. Tosato G, Seamon K, Goldman N, Sehgal P, May L, Washington G, Jones K, Pike S (1988) Monocyte-derived human B cell growth factor identified as interferon-beta 2(BSF2,IL-6). Science 239: 502–504

    Google Scholar 

  54. Vink A, Coulie P, Warnier G, Renauld JC, Stevens M, Donckers D, Van Snick J (1990) Mouse plasmacytoma growth in vivo: enhancement by IL-6 and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med 172: 997–1000

    Google Scholar 

  55. Wieser M, Bonifer R, Oster W, Lindemann A, Mertelsmann R, Herrmann F (1989) IL-4 induces secretion of G-CSF and M-CSF by peripheral blood monocytes. Blood 73: 1105–1108

    Google Scholar 

  56. Zhang XG, Klein B, Bataille R (1989) IL-6 is a potent myeloma cell growth factor in patients with aggressive MM. Blood 74: 11–13

    Google Scholar 

  57. Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B (1990) GM-CSF synergizes with IL-6 in supporting the proliferation of human myeloma cells. Blood 76: 2599–2605

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Internal Medicine, Academic Medical Center, Meibergdreef 9, NL-1105, AZ Amsterdam, The Netherlands

    M. H. J. van Oers & H. C. T. van Zaanen

  2. Department of Hematology, University Hospital Utrecht, The Netherlands

    H. M. Lokhorst

Authors
  1. M. H. J. van Oers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. C. T. van Zaanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. M. Lokhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Oers, M.H.J., van Zaanen, H.C.T. & Lokhorst, H.M. Interleukin-6, a new target for therapy in multiple myeloma?. Ann Hematol 66, 219–223 (1993). https://doi.org/10.1007/BF01738469

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01738469

Key words

Search

Navigation